Author:
Merkel C.,Whicher C. H.,Bomanji J.,Herrmann K.,Ćwikła J.,Jervis N.,Wait S.,Chiti A.
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine
Reference26 articles.
1. European Medicines Agency. Xofigo: EPAR - medicine overview. In: Xofigo. 2018. https://www.ema.europa.eu/en/documents/overview/xofigo-epar-medicine-overview_en.pdf. Accessed 10/01/20.
2. European Medicines Agency. Lutathera: EPAR - Summary for the public. In: Lutathera. 2018. https://www.ema.europa.eu/en/documents/overview/lutathera-epar-summary-public_en.pdf. Accessed 02/04/19.
3. Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9:16932–50. https://doi.org/10.18632/oncotarget.24524.
4. Nilsson S. Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer. Curr Oncol Rep. 2016;18:14. https://doi.org/10.1007/s11912-015-0495-4.
5. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95. https://doi.org/10.1007/s00259-017-3882-2.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献